Alterations in JAK-STAT and BCL2 family member gene expression induced by ruxolitinib and venetoclax. Patient-derived malignant CTCL samples of high-responders and low-responders were incubated with 1 µM ruxolitinib, 0.2 µM venetoclax, or combination for 24 hours. Results expressed as fold change from untreated vehicle controls in high-responders (A) and low-responders (B). Notably, high-responders showed an average of ∼38-fold decrease in BCL2 expression when incubated with ruxolitinib alone or in combination, substantially greater than the fold decrease seen in low-responders (approximately fivefold).